Zdrowie i gospodarka · 20/11/2015
FDA Clears LIPTRUZET Tablets for Approval
The FDA has determined that LIPTRUZET tablets, containing ezetimibe and atorvastatin, were not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of generic versions of the medication.